Udvalget for Humanmedicinske Lægemidler (CHMP) fandt, at fordelene ved OptiMARK opvejer risiciene ved anvendelse ved MRI- scanning af centralnervesystemet og leveren.
The Committee for Medicinal Products for Human Use (CHMP) decided that OptiMARK’ s benefits are greater than its risks for use with MRI of the central nervous system and liver.